Up next

Autoplay

BRUKINSA® (zanubrutinib) overview with Dr Anthony Nguyen

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Dr Nguyen, a community-based medical oncologist, discusses the benefits of BRUKINSA for his patients with B-cell malignancies, including those with chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WM).

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:
• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
• Waldenström's macroglobulinemia (WM)
• Mantle cell lymphoma (MCL) who have received at least one prior therapy
• Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen
• Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy

The MCL, MZL and FL indications are approved under accelerated approval based on overall response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and embryo-fetal toxicity. In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

Please see full Prescribing Information: brukinsa.com/prescribing-information.pdf

This content is intended for US Healthcare Professionals only. Learn more at:
https://www.brukinsa.com/hcp/

Show more
0 Comments sort Sort By

Up next

Autoplay